News | February 13, 2021
Jubilant Pharmova recovers: ICICI Securities
Jubilant announced the completion of demerger of pharma and LSI business into two separate companies
Jubilant announced the completion of demerger of pharma and LSI business into two separate companies
The pandemic has provided tailwinds in terms of access to rural healthcare and India’s emergence as a vaccine powerhouse
The centralized marketing authorization granted by the EC is valid in all EU Member
The medical device Sector in India suffers from a considerable cost of manufacturing disability.
The DREAM-ND Phase III trial has now enrolled 588 CKD patients not-on-dialysis.
The company's business in India geography posted strong growth during the quarter as it grew by 20% on a y-o-y basis and registered revenues of Rs. 1,643 crore.
The partnership is a significant step in delivering advanced cancer therapies to patients.
EBITDA for the quarter stood at Rs. 427 crore and Net Profit was at Rs. 169 crore. Our Core EBITDA margins stood at 31%.
With a mix of vaccines targeting different stages of COVID-19, the company is eyeing huge market potential
Novasep's viral vector business is an excellent strategic fit as Thermo Fisher continues to expand its capabilities for cell and gene vaccines and therapies globally," said Michel Lagarde, executive vice president, Thermo Fisher.
Subscribe To Our Newsletter & Stay Updated
